Bionest

ASH 2021 Update: Part 2

A look at new hematology therapy developments for hemophilia, beta thalassemia and sickle cell disease presented at ASH 2021.

Bionest

ASH 2021 Update: Part One

Are anti-CD38 antibodies & CAR-T treatments living up to their promise for multiple myeloma patients? We examine clinical trial results shared at ASH2021